Latest news
A new med is called a non-stimulant. The label says stimulant. The trials say less. - Psychology TodayPsychology Today · Sat, 08 Aug 2026 17:45:01 GMTCentanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD - Psychiatric TimesPsychiatric Times · Mon, 03 Aug 2026 18:23:02 GMTA New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval - Psychiatric TimesPsychiatric Times · Fri, 31 Jul 2026 16:39:39 GMTCentanafadine Receives FDA Approval for the Treatment of ADHD - ADDitudeADDitude · Wed, 29 Jul 2026 07:00:00 GMTFDA Approves First-in-Class Triple Reuptake Inhibitor for ADHD - Medical DialoguesMedical Dialogues · Tue, 28 Jul 2026 15:15:17 GMTFDA approves Simtriyo, the first triple reuptake inhibitor for ADHD - Managed Healthcare ExecutiveManaged Healthcare Executive · Mon, 27 Jul 2026 07:00:00 GMTFirst-in-Class Drug for ADHD Wins FDA Approval - MedPage TodayMedPage Today · Mon, 27 Jul 2026 07:00:00 GMTOtsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD - FirstWord PHARMAFirstWord PHARMA · Sun, 26 Jul 2026 07:00:00 GMT